Notch and NF-kB signaling pathways regulate miR-223/FBXW7 axis in T-cell acute lymphoblastic leukemia

Leukemia

Volumn 28, Issue 12, 2014, Pages 2324-2335

  Kumar, V ^a   Palermo, R ^b   Talora, C ^a   Campese, A F ^a   Checquolo, S ^c   Bellavia, D ^a   Tottone, L ^a   Testa, G ^a   Miele, E ^b   Indraccolo, S ^d   Amadori, A ^d,e   Ferretti, E ^f   Gulino, A ^a,b,g   Vacca, A ^f   Screpanti, I ^a,b,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g IRCCS NEUROMED   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; FBXW7 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MICRORNA 223; MICRORNA 31; MICRORNA 337 5P; MICRORNA 363; MICRORNA 546; MICRORNA 675 3P; MICRORNA 679; MICRORNA 875 3P; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH3 RECEPTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; DIPEPTIDE; F BOX PROTEIN; FBXW7 PROTEIN, HUMAN; MIRN223 MICRORNA, HUMAN; N-(N-(3,5-DIFLUOROPHENACETYL)ALANYL)PHENYLGLYCINE TERT-BUTYL ESTER; SECRETASE; UBIQUITIN PROTEIN LIGASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CANCER INHIBITION; CANCER RESISTANCE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; JURKAT CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; T CELL ACUTE LYMPHOBLASTIC LEUKEMIA; T CELL LEUKEMIA; THYMOCYTE; TRANSCRIPTION INITIATION; TRANSCRIPTION INITIATION SITE; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CLUSTER ANALYSIS; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; RNA INTERFERENCE; TRANSGENIC MOUSE; TUMOR CELL LINE;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CLUSTER ANALYSIS; DIPEPTIDES; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; F-BOX PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; GENE SILENCING; HUMANS; MICE, TRANSGENIC; MICRORNAS; NF-KAPPA B; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, NOTCH; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES;

EID: 84925282873     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.133     Document Type: Article

References (59)

1. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999; 284: 770-776.
2. Radtke F, Wilson A, Mancini SJ, MacDonald HR. Notch regulation of lymphocyte development and function. Nat Immunol 2004; 5: 247-253.
3. Maillard I, Fang T, Pear WS. Regulation of lymphoid development, differentiation, and function by the Notch pathway. Annu Rev Immunol 2005; 23: 945-974.
4. Screpanti I, Bellavia D, Campese AF, Frati L, Gulino A. Notch, a unifying target in T-cell acute lymphoblastic leukemia? Trends Mol Med 2003; 9: 30-35.
5. Aster JC. Deregulated NOTCH signaling in acute T-cell lymphoblastic leukemia/lymphoma: new insights, questions, and opportunities. Int J Hematol 2005; 82: 295-301.
6. Grabher C, von Boehmer H, Look AT. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer 2006; 6: 347-359.
7. Pear WS, Aster JC, Scott ML, Hasserjian RP, Soffer B, Sklar J et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med 1996; 183: 2283-2291.
8. Bellavia D, Campese AF, Alesse E, Vacca A, Felli MP, Balestri A et al. Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice. EMBO J 2000; 19: 3337-3348.
9. Weng AP, Ferrando AA, Lee W, Morris JPT, Silverman LB, Sanchez-Irizarry C et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269-271.
10. Mansour MR, Linch DC, Foroni L, Goldstone AH, Gale RE. High incidence of Notch-1. mutations in adult patients with T-cell acute lymphoblastic leukemia. Leukemia 2006; 20: 537-539.
11. Bellavia D, Campese AF, Checquolo S, Balestri A, Biondi A, Cazzaniga G et al. Combined expression of pTalpha and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. Proc Natl Acad Sci USA 2002; 99: 3788-3793.
12. Espinosa L, Cathelin S, D'Altri T, Trimarchi T, Statnikov A, Guiu J et al. The Notch/Hes1 pathway sustains NF-kappaB activation through CYLD repression in T cell leukemia. Cancer Cell 2010; 18: 268-281.
13. Vacca A, Felli MP, Palermo R, Di Mario G, Calce A, Di Giovine M et al. Notch3 and pre-TCR interaction unveils distinct NF-kappaB pathways in T-cell development and leukemia. EMBO J 2006; 25: 1000-1008.
14. Vilimas T, Mascarenhas J, Palomero T, Mandal M, Buonamici S, Meng F et al. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med 2007; 13: 70-77.
15. Felli MP, Vacca A, Calce A, Bellavia D, Campese AF, Grillo R et al. PKC theta mediates pre-TCR signaling and contributes to Notch3-induced T-cell leukemia. Oncogene 2005; 24: 992-1000.
16. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004; 303: 83-86.
17. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269.
18. Schotte D, Pieters R, Den Boer ML. MicroRNAs in acute leukemia: from biological players to clinical contributors. Leukemia 2012; 26: 1-12.
19. Agirre X, Martinez-Climent JA, Odero MD, Prosper F. Epigenetic regulation of miRNA genes in acute leukemia. Leukemia 2012; 26: 395-403.
20. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
21. Ferretti E, De Smaele E, Po A, Di Marcotullio L, Tosi E, Espinola MS et al. MicroRNA profiling in human medulloblastoma. Int J Cancer 2009; 124: 568-577.
22. De Smaele E, Ferretti E, Gulino A. MicroRNAs as biomarkers for CNS cancer and other disorders. Brain Res 2010; 1338: 100-111.
23. Wang Z, Li Y, Kong D, Ahmad A, Banerjee S, Sarkar FH. Cross-talk between miRNA and Notch signaling pathways in tumor development and progression. Cancer Lett 2010; 292: 141-148.
24. Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 2009; 69: 7569-7576.
25. Li X, Sanda T, Look AT, Novina CD, von Boehmer H. Repression of tumor suppressor miR-451 is essential for NOTCH1-induced oncogenesis in T-ALL. J Exp Med 2011; 208: 663-675.
26. Kuang W, Tan J, Duan Y, Duan J, Wang W, Jin F et al. Cyclic stretch induced miR-146a upregulation delays C2C12 myogenic differentiation through inhibition of Numb. Biochem Biophys Res Commun 2009; 378: 259-263.
27. Ghisi M, Corradin A, Basso K, Frasson C, Serafin V, Mukherjee S et al. Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. Blood 2011; 117: 7053-7062.
28. Song G, Zhang Y, Wang L. MicroRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. J Biol Chem 2009; 284: 31921-31927.
29. Mavrakis KJ, Wolfe AL, Oricchio E, Palomero T, de Keersmaecker K, McJunkin K et al. Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat Cell Biol 2010; 12: 372-379.
30. Palermo R, Checquolo S, Giovenco A, Grazioli P, Kumar V, Campese AF et al. Acetylation controls Notch3 stability and function in T-cell leukemia. Oncogene 2012; 31: 3807-3817.
31. Talora C, Cialfi S, Oliviero C, Palermo R, Pascucci M, Frati L et al. Cross talk among Notch3, pre-TCR, and Tal1 in T-cell development and leukemogenesis. Blood 2006; 107: 3313-3320.
32. Talora C, Sgroi DC, Crum CP, Dotto GP. Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev 2002; 16: 2252-2263.
33. Bellavia D, Mecarozzi M, Campese AF, Grazioli P, Talora C, Frati L et al. Notch3 and the Notch3-upregulated RNA-binding protein HuD regulate Ikaros alternative splicing. EMBO J 2007; 26: 1670-1680.
34. Barbarulo A, Grazioli P, Campese AF, Bellavia D, Di Mario G, Pelullo M et al. Notch3 and canonical NF-kappaB signaling pathways cooperatively regulate Foxp3 transcription. J Immunol 2011; 186: 6199-6206.
35. Canettieri G, Santaguida MG, Antonucci L, Della Guardia M, Franchi A, Coni S et al. CCAAT/enhancer-binding proteins are key regulators of human type two deiodinase expression in a placenta cell line. Endocrinology 2012; 153: 4030-4038.
36. Jarriault S, Brou C, Logeat F, Schroeter EH, Kopan R, Israel A. Signalling downstream of activated mammalian Notch. Nature 1995; 377: 355-358.
37. Talora C, Campese AF, Bellavia D, Pascucci M, Checquolo S, Groppioni M et al. Pre-TCR-triggered ERK signalling-dependent downregulation of E2A activity in Notch3-induced T-cell lymphoma. EMBO Rep 2003; 4: 1067-1072.
38. Primi D, Clynes RA, Jouvin-Marche E, Marolleau JP, Barbier E, Cazenave PA et al. Rearrangement and expression of T cell receptor and immunoglobulin loci in immortalized CD4-CD8-T cell lines. Eur J Immunol 1988; 18: 1101-1109.
39. Mavrakis KJ, Van Der Meulen J, Wolfe AL, Liu X, Mets E, Taghon T et al. A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nat Genet 2011; 43: 673-678.
40. Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C et al. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell 2005; 123: 819-831.
41. Fukao T, Fukuda Y, Kiga K, Sharif J, Hino K, Enomoto Y et al. An evolutionarily conserved mechanism for microRNA-223 expression revealed by microRNA gene profiling. Cell 2007; 129: 617-631.
42. He KL, Ting AT. Essential role for IKKgamma/NEMO in TCR-induced IL-2 expression in Jurkat T cells. Eur J Immunol 2003; 33: 1917-1924.
43. Mansour MR, Sanda T, Lawton LN, Li X, Kreslavsky T, Novina CD et al. The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia. J Exp Med 2013; 210: 1545-1557.
44. Agnusdei V, Minuzzo S, Frasson C, Grassi A, Axelrod F, Satyal S et al. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts. Leukemia 2013; 28: 278-288.
45. O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gammasecretase inhibitors. J Exp Med 2007; 204: 1813-1824.
46. Wang Z, Inuzuka H, Zhong J, Wan L, Fukushima H, Sarkar FH et al. Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett 2012; 586: 1409-1418.
47. Oberg C, Li J, Pauley A, Wolf E, Gurney M, Lendahl U. The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog. J Biol Chem 2001; 276: 35847-35853.
48. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 2004; 23: 2116-2125.
49. Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 2001; 413: 316-322.
50. Gusscott S, Kuchenbauer F, Humphries RK, Weng AP. Notch-mediated repression of miR-223 contributes to IGF1R regulation in T-ALL. Leuk Res 2012; 36: 905-911.
51. Medyouf H, Gao X, Armstrong F, Gusscott S, Liu Q, Gedman AL et al. Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. Blood 2010; 115: 1175-1184.
52. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991; 66: 649-661.
53. Lee SY, Kumano K, Masuda S, Hangaishi A, Takita J, Nakazaki K et al. Mutations of the Notch1 gene in T-cell acute lymphoblastic leukemia: analysis in adults and children. Leukemia 2005; 19: 1841-1843.
54. Ferrando A. NOTCH mutations as prognostic markers in T-ALL. Leukemia 2010; 24: 2003-2004.
55. Ferrando AA, Look AT. Gene expression profiling in T-cell acute lymphoblastic leukemia. Semin Hematol 2003; 40: 274-280.
56. Correia NC, Durinck K, Leite AP, Ongenaert M, Rondou P, Speleman F et al. Novel TAL1 targets beyond protein-coding genes: identification of TAL1-regulated microRNAs in T-cell acute lymphoblastic leukemia. Leukemia 2013; 27: 1603-1606.
57. Wang Z, Fukushima H, Gao D, Inuzuka H, Wan L, Lau AW et al. The two faces of FBW7 in cancer drug resistance. BioEssays 2011; 33: 851-859.
58. Park MJ, Taki T, Oda M, Watanabe T, Yumura-Yagi K, Kobayashi R et al. FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol 2009; 145: 198-206.
59. Thompson BJ, Buonamici S, Sulis ML, Palomero T, Vilimas T, Basso G et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med 2007; 204: 1825-1835.